RECRUITING

Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Thought-Action-Fusion (TAF) is a cognitive bias that posits (1) having unwanted thoughts is morally equivalent to acting upon the thoughts (TAF-Moral; e.g., "Thinking about harming a child is as immoral as actually harming a child") and (2) having unwanted thoughts will increase the likelihood of the thoughts happening in real life (TAF-Likelihood; e.g., "My mother will get into a car accident, because I thought about it"). Given its central role in the development and maintenance of OCD, TAF has emerged as a potential treatment target for obsessive-compulsive disorder (OCD). Previous research has demonstrated that TAF is indeed a malleable construct. This study aims to examine the effects of a multi-session, personalized cognitive bias modification (CBM) for thought-action-fusion (TAF) on improving obsessive-compulsive (OC) symptoms in a college sample.

Official Title

Effects of Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion Among Adults with Obsessive-Compulsive Symptoms: a Randomized Controlled Trial

Quick Facts

Study Start:2024-04-18
Study Completion:2026-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06731426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * A score of 18 or higher on the Dimensional Obsessive-Compulsive Scale (DOCS)
  2. * Aged 18 or higher
  3. * Access to a mobile device (i.e., smartphone)
  1. * Self-reported visual impairment that cannot be adjusted and will prevent them from clearly recognizing words and pictures on mobile screen
  2. * Self-reported history of a bipolar disorder or psychotic disorder on a Diagnostic History Scale (DHS)
  3. * Inability to adequately understand the study procedure as determined by the responses to comprehension questions provided at the time of the consent

Contacts and Locations

Study Contact

Hanjoo Lee, PhD
CONTACT
(414) 229-5858
leehj@uwm.edu
Minjee Kook, BA
CONTACT
mkook@uwm.edu

Principal Investigator

Hanjoo Lee, PhD
PRINCIPAL_INVESTIGATOR
University of Wisconsin, Milwaukee

Study Locations (Sites)

UWM Anxiety Disorders Laboratory
Milwaukee, Wisconsin, 53211
United States

Collaborators and Investigators

Sponsor: Han Joo Lee

  • Hanjoo Lee, PhD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Milwaukee

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-18
Study Completion Date2026-05-31

Study Record Updates

Study Start Date2024-04-18
Study Completion Date2026-05-31

Terms related to this study

Keywords Provided by Researchers

  • Cognitive Bias Modification
  • Personalization

Additional Relevant MeSH Terms

  • OCD